Description: MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Home Page: meipharma.com
0JW9 Technical Analysis
9920 Pacific Heights Blvd.
San Diego,
CA
92121
United States
Phone:
(858) 369-7100
Officers
| Name | Title |
|---|---|
| Ms. Yomara Gomez-Naiden | Senior Vice President of Operations & Quality |
| Ms. Nicole Chyoko Iida | Vice President of Legal Affairs |
| Ms. Anne Frese | Chief People Officer |
| Dr. Robert D. Mass | Strategic Advisor |
| Mr. David A. Walsey J.D., L.L.M. | Senior Vice President of Corporate Affairs |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: US Dollar ($)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Commercial & Professional Services |
| GIC Industry: | Commercial Services & Supplies |
| GIC Sub-Industry: | Environmental & Facilities Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 2.9457 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 28 |